Yin Wu

Yin Wu has extensive experience in the pharmaceutical industry, having served as Executive Director at Schrödinger from January 2020 to February 2022, overseeing early clinical development in Non-Hodgkin Lymphoma B Cell Malignancies. Prior roles at Schrödinger included Senior Director and Senior Research Leader, both focused on early clinical development. At Pharmaron, Yin Wu was Director of Business Development, facilitating connections between early clinical units and pharmaceutical companies for Phase I and single-site Phase II studies. A significant tenure at Merck spanned from August 2009 to June 2017, where Yin Wu advanced from Senior Research Biologist to Principal Scientist, leading projects in Cardiometabolic Diseases. Academic training includes a Ph.D. in Pharmacology from the University of Pennsylvania and a Master's in Neuropharmacology from Peking University, along with postdoctoral work at UT Southwestern Medical Center.